Corbus Reports 47.6% ORR in HNSCC and Raises $75M in Q4 Offering
Corbus presented Phase 1/2 ESMO 2025 data showing CRB-701 achieved 47.6% unconfirmed ORR in HNSCC and 37.5% in cervical cancer, with no grade 4/5 adverse events. The company completed a $75 million offering in Q4 2025 and held $163.3 million cash at year-end, extending its runway into 2028.
1. Q4 Financial Results and Cash Position
Corbus reported a Q4 2025 net loss of $20.6 million ($1.25 per share) versus $9.5 million ($0.78 per share) in Q4 2024, driven by a $9.4 million increase in clinical development expenses. The completion of a $75 million public offering in Q4 2025 boosted year-end cash, cash equivalents and investments to $163.3 million, funding operations into 2028.
2. CRB-701 Phase 1/2 ESMO 2025 Data
At ESMO 2025, CRB-701, a Nectin-4 ADC for HNSCC and cervical cancer, showed unconfirmed objective response rates of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in bladder cancer at the 3.6 mg/kg dose. Safety was favorable with no grade 4/5 treatment-related adverse events, low peripheral neuropathy and skin toxicity; registrational study discussions and mid-2026 monotherapy data are expected next.
3. CRB-913 Phase 1a Obesity Program
CRB-913, an oral CB1 inverse agonist, delivered 2.9% placebo-adjusted weight loss at 14 days in the 150 mg/day cohort with no GI adverse events or neuropsychiatric signals. The 12-week CANYON-1 dose-ranging study (n=240) remains on track for completion in summer 2026, aiming to confirm durability and safety in chronic obesity management.